Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer (PCM304)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01875393|
Recruitment Status : Completed
First Posted : June 11, 2013
Last Update Posted : April 19, 2016
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: TOOKAD® Soluble||Phase 3|
The study is designed as a multicenter, single-arm, open label, 12 months follow-up clinical trial. Men with localized prostate cancer will be treated with TOOKAD® Soluble VTP under general anesthesia.
Patients will be followed-up for 12 months with patient questionnaires on QoL, erectile and urinary functions, clinical evaluation with study visits at 1, 3, 6 and 12 months , Prostate Specific Antigen(PSA) testing at 3, 6 and 12 months. In addition, they will have biopsy at 6 months (± 2) and 12 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||81 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the Efficacy,Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||March 2015|
Experimental: TOOKAD® Soluble
TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
Drug: TOOKAD® Soluble
The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
Other Name: WST11
- To confirm that a significant proportion of patients will be prostate cancer free on the biopsy. [ Time Frame: Month 12 ]Number of patients with a negative biopsy.
- Changes in urinary and erectile functions and their potential impact on quality of life using International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) and the General quality of life (EQ5D) questionnaires. [ Time Frame: Screening, 1, 3, 6 and 12 months after completing treatment ]Patients' reported outcome measures (PROMs) impairment: urinary symptoms using IPSS and erectile functions using IIEF. Quality of life using EQ5D will also be described
- The rate of adverse events. [ Time Frame: Screening-Month 12 ]Adverse event reporting.
- The overall cancer burden in the prostate determined by biopsy as compared to baseline. [ Time Frame: Month 12 ]Total length of cancer present in all cores taken in any given biopsy session
- The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death [ Time Frame: Screening-Month 12 ]Severe prostate cancer related events: cancer extension to T3, metastasis or prostate cancer-related death.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01875393
|Hospital General Tlahuac|
|Mexico DF, Mexico, 13278|
|Pan-American Medical Research Institute (PAMRI) then moved to Consultario del Dr Rodriguez|
|Panama city, Panama|
|Hospital Nacional Cayetano Heredia|
|San Martin de Porres, Peru|
|Principal Investigator:||Jose Arturo Rodriguez Rivera, Dr||Hospital General Tlahuac|
|Principal Investigator:||Mary Lol Ve Mendoza Medina, Dr||Hospital General Tlahuac|
|Principal Investigator:||Luis Zegarra Montes, Professor||Hospital Nacional Cayetano Heredia|
|Principal Investigator:||Ramón Rodriguez, Professor||Pan-American Medical Research Institute (PAMRI) then moved to Consultario del Dr Rodriguez|